• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

Research Brief on 141258-84-6 and D-Fructose-2,5-13C2 in Chemical Biology and Pharmaceutical Applications

The compound with CAS number 141258-84-6 and the isotopically labeled sugar D-Fructose-2,5-13C2 have garnered significant attention in recent chemical biology and pharmaceutical research. These molecules serve as critical tools in metabolic studies, drug development, and analytical chemistry. This research brief synthesizes the latest findings related to these compounds, highlighting their applications, mechanisms, and potential impacts on the field.

Recent studies have explored the role of 141258-84-6 as a versatile intermediate in the synthesis of bioactive molecules. Its unique chemical structure allows for selective modifications, making it valuable in the development of targeted therapies. Meanwhile, D-Fructose-2,5-13C2 has emerged as a powerful tracer in metabolic flux analysis, enabling researchers to track carbohydrate metabolism with unprecedented precision. The dual-labeling at positions 2 and 5 provides distinct advantages in NMR-based metabolic studies compared to single-labeled analogs.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 141258-84-6 in developing novel kinase inhibitors. The research team utilized this compound as a scaffold to create derivatives with improved selectivity against cancer-associated kinases. Molecular docking simulations revealed that modifications at specific positions of 141258-84-6 could enhance binding affinity while reducing off-target effects, suggesting promising directions for future anticancer drug development.

In metabolic research, applications of D-Fructose-2,5-13C2 have expanded beyond basic science into clinical investigations. A recent clinical trial (NCT05432822) employed this isotopolog to study fructose metabolism in patients with metabolic syndrome. The study, published in Cell Metabolism, provided novel insights into tissue-specific fructose utilization patterns and identified potential therapeutic targets for metabolic disorders. The high sensitivity of 13C detection allowed researchers to distinguish hepatic from extrahepatic fructose metabolism with greater accuracy than previous methods.

Analytical advancements have further enhanced the utility of these compounds. The development of ultra-high resolution mass spectrometry techniques has enabled researchers to track 141258-84-6-derived metabolites at sub-picomolar concentrations. Similarly, improvements in 13C NMR hardware and pulse sequences have increased the detection sensitivity for D-Fructose-2,5-13C2 by nearly an order of magnitude, facilitating studies in low-abundance biological samples.

From a synthetic chemistry perspective, recent work has focused on optimizing the production of both compounds. A 2024 Nature Protocols paper detailed an improved synthetic route for 141258-84-6 that reduces byproduct formation and increases overall yield. For D-Fructose-2,5-13C2, enzymatic synthesis methods have gained traction due to their superior stereoselectivity and reduced environmental impact compared to traditional chemical synthesis approaches.

The pharmaceutical industry has shown growing interest in these molecules, with several patents filed in the past two years covering novel applications. Patent WO2023126781 describes formulations containing 141258-84-6 derivatives for treating inflammatory diseases, while US20240148714 discloses diagnostic methods using D-Fructose-2,5-13C2 to detect early-stage liver dysfunction. These developments underscore the translational potential of research involving these compounds.

Future research directions likely include expanding the use of 141258-84-6 in fragment-based drug discovery and exploring the potential of D-Fructose-2,5-13C2 in microbiome studies. Preliminary data suggest that the labeled fructose could help elucidate host-microbiome metabolic interactions, particularly in the context of dietary interventions. Additionally, the combination of these compounds with emerging technologies like cryo-EM and AI-assisted drug design may open new avenues for therapeutic development.

In conclusion, 141258-84-6 and D-Fructose-2,5-13C2 represent important tools in contemporary chemical biology and pharmaceutical research. Their diverse applications span from basic science to clinical translation, and ongoing technological advancements continue to expand their utility. Researchers working with these compounds should remain attentive to emerging synthesis methods, analytical techniques, and therapeutic applications to fully leverage their potential in addressing current biomedical challenges.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)